A Trial of M72/AS01E Vaccine to Prevent Tuberculosis. Reply
N Engl J Med
.
2020 Apr 16;382(16):1577.
doi: 10.1056/NEJMc2001364.
Authors
Dereck R Tait
1
,
Olivier Van Der Meeren
2
,
Mark Hatherill
3
Affiliations
1
IAVI, Cape Town, South Africa.
2
GlaxoSmithKline, Wavre, Belgium olivier.x.van-der-meeren@gsk.com.
3
South African Tuberculosis Vaccine Initiative, Cape Town, South Africa.
PMID:
32294369
DOI:
10.1056/NEJMc2001364
No abstract available
Publication types
Letter
Comment
MeSH terms
Humans
Tuberculosis Vaccines*
Tuberculosis*
Substances
Tuberculosis Vaccines